id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1976-N-0031-0023,FDA,FDA-1976-N-0031,Memorandum of Telephone Conversation between FDA/CDER and Schering Laboratories Medical Research,Other,Memorandum,2012-03-14T04:00:00Z,2012,3,2012-03-14T04:00:00Z,,2015-10-13T17:48:27Z,,0,0,090000648051bb5b
FDA-1976-N-0031-0025,FDA,FDA-1976-N-0031,Supplement from Richardson-Merrell Inc. (Vick Divisions Research and Development),Other,Supplement (SUP),2012-03-14T04:00:00Z,2012,3,2012-03-14T04:00:00Z,,2016-10-06T14:59:23Z,,0,0,090000648051bb6e
FDA-1976-N-0031-0024,FDA,FDA-1976-N-0031,"Notice on  Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products For Over-The-Counter (OTC) Human Use; Decision On Dosage Of Pseudoephedrine Preparations",Notice,General Notice,2012-03-14T04:00:00Z,2012,3,2012-03-14T04:00:00Z,,2016-01-21T15:28:44Z,,0,0,090000648051bb90
FDA-1976-N-0031-0026,FDA,FDA-1976-N-0031,Memorandum of Telephone Conversation between FDA/CDER and Vick Devisions Research & Development,Other,Memorandum,2012-03-14T04:00:00Z,2012,3,2012-03-14T04:00:00Z,,2016-10-05T14:42:39Z,,0,0,090000648051bb89